Haleon plc Form 6-K Summary
Business Context and Reporting Period
Haleon plc filed this Form 6-K for February 2024 as a foreign private issuer filing under Form 20-F. The filing furnishes Haleon’s preliminary full-year results for the year ended 31 December 2023. Haleon is a global consumer-health company operating across oral health, pain relief, respiratory health, digestive health, vitamins, minerals and supplements, and other categories.
Financial Metrics
The filing text identifies the preliminary 2023 full-year results but does not include the underlying results statement or clear values for revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics. The results were made available separately through an RNS link, Haleon’s investor-relations website, and the FCA National Storage Mechanism.
Changes Versus the Prior Comparable Period
The filing text does not provide financial comparisons with the prior year or quantify material changes.
Guidance, Outlook, Risks, and Unusual Items
- The filing announces an investor presentation and question-and-answer session featuring the chief executive officer and chief financial officer.
- No specific forward guidance, outlook figures, risk updates, contingencies, or unusual items are provided in the supplied filing text.
- The filing states that the information constitutes regulated information under the UK Financial Conduct Authority’s Disclosure and Transparency Rules.
Investor Verification Items
- Verify the complete preliminary 2023 results statement, including revenue growth, organic growth, operating profit, adjusted measures, earnings per share, and margins.
- Verify operating and free cash flow, capital expenditure, net debt, leverage, liquidity, and debt-maturity information.
- Review the company’s reconciliation of statutory to adjusted measures and any exceptional or one-time items.
- Check management’s 2024 guidance, outlook assumptions, dividend plans, and commentary on inflation, pricing, volume, foreign exchange, and category performance.
- Review the full results presentation and any subsequent disclosures for risks, contingencies, litigation, tax matters, and other material developments.